Drug Insights

How to Effectively Search for Budesonide on Synapse

15 March 2024
2 min read

Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years. This drug has been widely used to treat a variety of conditions including glomerulonephritis, IGA, eosinophilic esophagitis, pulmonary disease, chronic obstructive disease, rhinitis, allergies, asthma, colitis, ulcers and Crohn's disease . Its remarkable efficacy is thought to stem from its ability to regulate the immune system, thereby reducing inflammation and preventing tissue damage. Click on the image below to begin the exploration journey of Budesonide through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

ASLAN Pharmaceuticals Provides TREK-DX Update, Highlights Eblasakimab's Success in Dupilumab-Treated Atopic Dermatitis Cases
Latest Hotspot
3 min read
ASLAN Pharmaceuticals Provides TREK-DX Update, Highlights Eblasakimab's Success in Dupilumab-Treated Atopic Dermatitis Cases
14 March 2024
ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.
Read →
Targeted GPRC5D CAR-T Product: OriCAR-017
Targeted GPRC5D CAR-T Product: OriCAR-017
14 March 2024
In January, Oricell Therapeutics announced U.S. FDA approval for the IND application of OriCAR-017 to treat relapsed/refractory multiple myeloma (R/R MM).
Read →
MoonLake's Sonelokimab Shows Promising Six-Month Results for Psoriatic Arthritis Treatment at R&D Event
Latest Hotspot
3 min read
MoonLake's Sonelokimab Shows Promising Six-Month Results for Psoriatic Arthritis Treatment at R&D Event
14 March 2024
MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.
Read →
Your Ultimate Guide to Finding Prazosin on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Prazosin on Synapse
14 March 2024
Prazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.